德琪医药
ANTENGENE
SEHK: 6996.HK

Antengene and UCB Enter into Global License Agreement for ATG-201 (CD19 x CD3 TCE Designed for Autoimmune Diseases)

March 2026

Disclaimer

By attending the meeting where this presentation is made, or by reading the presentation materials, you agree to be bound by the following:

The information in this presentation has been prepared by representatives of Antengene Corporation Limited (the "Company" and, together with its subsidiaries, the "Group") for use in presentations by the Group for information purpose. No part of this presentation will form the basis of, or be relied on in connection with, any contract or commitment or investment decision.

Certain statements contained in this presentation and in the accompanying oral presentation, may constitute forward-looking statements. Examples of such forward-looking statements include those regarding investigational drug candidates and clinical trials and the status and related results thereto, as well as those regarding continuing and further development and commercialization efforts and transactions with third parties. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the global and regional regulatory environment in the jurisdictions in which the Company's does business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational drug candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company's current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of the Company's drug candidates, final and quality controlled verification of data and the related analyses, the expense and uncertainty of obtaining regulatory approval, the possibility of having to conduct additional clinical trials and the Company's reliance on third parties to conduct drug development, manufacturing and other services. Further, even if regulatory approval is obtained, pharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition. These statements are also subject to a number of material risks and uncertainties that are described in the Company's prospectus published onto the websites of the Company and The Stock Exchange of Hong Kong Limited and the announcements and other disclosures we make from time to time. The reader should not place undue reliance on any forward-looking statements included in this presentation or in the accompanying oral presentation. These statements speak only as of the date made, and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "believe," "expects," "may," "will," "could," "should," "shall," "risk," "intends," "estimates," "plans," "predicts," "continues," "assumes," "positioned" or "anticipates" or the negative thereof, other variations thereon or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. The information set out herein may be subject to updating, revision, verification and amendment and such information may change materially.

This presentation and the information contained herein is solely for your information and may not be reproduced or redistributed in any manner to any other person, in whole or in part. In particular, neither the information contained in this presentation nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in any jurisdiction which prohibits the same except in compliance with applicable securities laws. This presentation and the accompanying oral presentation contains data and information obtained from third-party studies and internal company analysis of such data and information. We have not independently verified the data and information obtained from these sources.

By attending this presentation, you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Group and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Group.

1

Opening Remarks

ANTENGENE

Antengene's Best / First-in-Class Pipeline: Advancing Next-Generation ADCs and Proprietary Novel TCEs for Oncology and Autoimmune Diseases

ANTENGENE

Next Generation ADCs

AnTenGager™ Proprietary TCE Platform

(2nd Generation "2+1" TCE Platform with Steric Hindrance Masking Technology)

Multiple APAC Markets Commercialization

* Approved markets in China also includes Taiwan, Hong Kong, and Macau

Antibody Drug Conjugates (ADCs)

ATG-022 (CLDN18.2) *Phase II*	CLDN18.2+ Gastric Cancer (GC) and Other Solid Tumors	CLDN18.2 ADC with Efficacy Across the Widest Patient Population; BTD in GC
ATG-125 (B7-H3 x PD-L1) *Pre-clinical*	Solid Tumors	IO+ADC in One Drug
CD24 *Pre-clinical*	Solid Tumors	IO+ADC in One Drug

Immuno-Oncology (IO)

ATG-037 (CD73) *Phase Ib/II*	CPI-resistant Melanoma and Non-small Cell Lung Cancer	Oral Bioavailable; Demonstrated Efficacy in CPI-resistant Patients
ATG-101 (PD-L1 x 4-1BB) *Phase I*	Solid Tumors	No Liver Toxicity

Autoimmune Diseases

ATG-201 (CD19 x CD3) *IND submissions expected 1Q26*	B Cell Driven Autoimmune Diseases	Deep B Cell Depletion with Low CRS
ATG-207 (Undisclosed Bifunctional Biologics) *Discovery*	T Cell Driven Autoimmune Diseases	First-in-Class; Induces T_{reg} and T Cell Exhaustion

T Cell Engagers (TCEs)

ATG-201 (CD19 x CD3) *IND submissions expected 1Q26*	B Cell Driven Autoimmune Diseases	Deep B Cell Depletion with Low CRS
ATG-106 (CDH6 x CD3) *Pre-clinical*	Ovarian Cancer and Kidney Cancer	First-in-Class CDH6 TCE
ATG-112 (ALPPL2 x CD3) *Pre-clinical*	Gynecological Tumors and Lung Cancer	First-in-Class ALPPL2 TCE
ATG-110 (LY6G6D x CD3) *Pre-clinical*	Microsatellite Stable (MSS) Colorectal Cancer	For IO-resistant Colorectal Cancer
ATG-021 (GPRC5D x CD3) *Pre-clinical*	Multiple Myeloma	
ATG-102 (LILRB4 x CD3) *Pre-clinical*	Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia	Biparatopic
ATG-107 (FLT3 x CD3) *Pre-clinical*	Acute Myeloid Leukemia	
ATG-115 (Undisclosed Bispecific TCE) *Pre-clinical*	Liver Cancer	Novel TAA Discovered by AI
Undisclosed Trispecific TCE *Discovery*	Metastatic Castration-resistant Prostate Cancer	First-in-Class
Undisclosed Trispecific TCE *Discovery*	Small Cell Lung Cancer and Neuroendocrine Tumors	First-in-Class

Antengene's Proven Global Clinical Development and Regulatory Track Record

ANTENGENE

5
Regions with Clinical Trials

32
IND Approvals

6
First-in-human (FIH) Programs

70
Sites with FIH Collaboration

29
NDA/sNDA Filings

10
Approved Markets

5
Reimbursed Markets

2

Global License Agreement

ANTENGENE

Antengene Enter into a Worldwide Licensing Agreement with UCB for ATG-201 (CD19 x CD3 TCE)

ANTENGENE

Combining Antengene's Discovery Platform and Clinical Execution Capabilities with UCB's Immunology Leadership to Accelerate ATG-201 Development on a Global Scale

Worldwide Exclusive Rights of ATG-201

- ✓ Underscores AnTenGager™ platform's unique capability in developing next generation TCEs with broad applicability
- ✓ Novel B cell-depleting immune cell engager designed to provide targeted, durable, and scalable treatment option for immunological diseases, and a potential disruptive therapeutic modality
- ✓ Antengene will complete First-In-Human Phase 1 Studies in China and Australia

ANTENGENE
Licensor

ucb
Licensee

Total Deal Value of ~US$1.2B

Upfront Payment and Near Term Milestone Payments	Development & Commercial Milestone Payments	Royalty Payments
US$80M *(US$60M Upfront Payment; US$20M Near-Term Milestone Payments)*	**US$1.1B**	**Tiered Royalties on Net Sales**

UCB Company Overview

Global biopharma company

Est. **1928** Legacy of scientific excellence

Revenue €7.7 B (+26%)*

Sustainability as business approach

Listed on Euronext Brussels

Areas of Focus

Neurology

Immunology

UCB's World

>3.1 M patients accessed our solutions*

Present in **36 countries***

~10,100 employees*

R&D spend **24% of revenue***

Inspired by **patients.** Driven by **science.**

*As of December 2025.

Our Partner: UCB, a Global Biopharma with Leading Immunology Expertise and Commercial Capabilities

ANTENGENE

Leading Global Biopharma in Immunology and Neurology

Inspired by **patients.**
Driven by **science.**

~100 Years
Excellence in Biopharmaceuticals

€7,741 Million
Revenue in 2025

>9,000
Employees

86%
Successful Phase III Studies
(vs. Industry Average of 56-58%)*

Established Multi-product Global Immunology Franchise

	Molecule	Mechanism	Indications
Approved Product	Bimzelx® (bimekizumab)	IL-17A/F Inhibitor	Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa, Ankylosing Spondylitis
Approved Product	RYSTIGGO® rozanolixizumab	Anti-FcRn	Generalized Myasthenia Gravis
Approved Product	ZILBRYSQ™ zilucoplan	C5 Inhibitor	Generalized Myasthenia Gravis
Approved Product	cimzia® (certolizumab pegol)	Anti-TNF	Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis, Non-radiographic Axial Spondyloarthritis, Crohn's Disease
R&D	**Dapirolizumab pegol**	Anti-CD40L	Systemic Lupus Erythematosus (Ongoing Phase III)
R&D	galvokimig	IL-13 & IL-17 A/F	Phase IIb for Atopic Dermatitis (Started in 2025)

3

AnTenGager™ TCE Platform

ANTENGENE

AnTenGager™ TCE 2.0 with Steric Hindrance-Masking Technology Enable Broad Applications Across Various Therapeutic Areas

ANTENGENE

Proprietary AnTenGager™ TCE Platform

Hematological Malignancies

ATG-021 (GPRC5D x CD3)
Multiple Myeloma

ATG-102 (LILRB4 x CD3)
Acute Myeloid Leukemia and
Chronic Myelomonocytic Leukemia

ATG-107 (FLT3 x CD3)
Acute Myeloid Leukemia

Solid Tumors

ATG-106 (CDH6 x CD3)
Ovarian Cancer and Kidney Cancer

ATG-112 (ALPPL2 x CD3)
Gynecological Tumors, Lung and Pancreatic Cancers

ATG-110 (LY6G6D x CD3)
Microsatellite Stable (MSS) Colorectal Cancer

ATG-115 (Undisclosed TCE)
Liver Cancer

Undisclosed Trispecific TCE
Metastatic Castration-resistant Prostate Cancer

Undisclosed Trispecific TCE
Small Cell Lung Cancer and Neuroendocrine Tumors

Autoimmune Diseases

ATG-201 (CD19 x CD3) – Licensed to UCB
B Cell Related Autoimmune Diseases

Undisclosed Trispecific TCEs
B Cell Related Autoimmune Diseases

"2+1" Bivalent Binding to DAA to Increase Avidity and Specificity

Conditional T cell Binding and Activation via Steric Hindrance

Proprietary Anti-CD3 Library (Affinity: 10^{-6}M to 10^{-9}M) Binding CD3εγ/εσ Complex with Fast On/Fast Off Binding Kinetics

AnTenGager™, a Novel Second Generation "2+1" TCE Platform with Steric Hindrance-masking Technology Enabling the Creation of TCEs with Enhanced Therapeutic Effect and Safety

ANTENGENE

Features of AnTenGager™ TCEs



"Plug and Play" Disease Associated Antigens (DAA)

- Compatible with diverse DAAs, enabling the discovery & development of TCEs across multiple therapeutic areas

Bivalent Binding of DAA

- Enables the targeting of **low-expressing target**

Proprietary CD3 Sequences (Patented)

- Binds to a **unique conformational epitope** (CD3εγ or CD3εσ complex), with **fast-on-fast-off binding kinetics**
- **Stronger T cell dependent cytotoxicity** and **reduced cytokine release**

Steric Hindrance Masking Technology

- Reduced risk of **hook effect** and **cytokine release syndrome (CRS)**



Target-Dependent CD3 Binding and Cytotoxicity



CD3 Binding Site of AnTenGager™ TCE is Concealed by DAA Fab Arm

ANTENGENE

AnTenGager™ Platform













- The CD3 binding site is **tightly concealed** by the constant region of DAA-targeting Fab arms in the unbound state due to **steric hindrance**

CD3 Binding Site

Fabx3 Platform





Segal, N.H. et al. Annals of Oncology, Volume 28, v134



- Fabx3 2+1 format maintains continuous exposure of CD3 binding sites due to the higher rigidity of its Fab arms

AnTenGager™ TCEs Induced Less T Cell Exhaustion vs First Generation TCEs

ANTENGENE

ATG-201



Benchmark 1



Benchmark 2

Benchmark 3







AnTenGager™ TCE 2.0: Overcoming CRS Barriers and Preventing T Cell Exhaustion to Enable Broader, More Effective, and Safer Therapeutic Applications

ANTENGENE



Minimizing Off-target T Cell Activation

Steric Hindrance Masking Technology

- **Minimizes off-target T cell activation and cytokine release** through target-dependent CD3 activation, enabling a safer therapeutic window and preventing T cell exhaustion
- Compared with protease-dependent shielding TCEs that require the tumor microenvironment; **AnTenGager™ TCEs are independent of the TME and can be used for broader indications beyond solid tumors**

Minimizing On-target T Cell Activation

Proprietary Anti-CD3 Sequences

- **Minimizes on-target T cell activation and cytokine release** by binding to a **unique conformational epitope** with **fast-on-fast-off** binding kinetics while maintaining potent T cell activation

- **Enhances Efficacy**
- **Improves Safety**
- **Prevents T Cell Exhaustion**
- **Minimizes Hook Effect**

ATG-201 – Licensed to UCB

CD19 x CD3 TCE for B Cell Related Autoimmune Diseases

ATG-201: CD19 x CD3 TCE 2.0 With Ability to Deeply Deplete B Cells for the Treatment of Autoimmune Diseases

ANTENGENE

ATG-201 is a CD19 x CD3 TCE with Target Dependent T Cell Activation

B Cell Depletion Therapy with ATG-201 to Treat Autoimmune Diseases





B Cell Depletion Leads to the Remission of Autoimmune Diseases

ATG-201 Demonstrated Deeper and More Durable *In Vivo* B Cell Depletion Compared to Benchmark in CD34+ Cell Humanized Mice

ANTENGENE

- **ATG-201:** A single dose **completely and deeply depleted B cells** in CD34 humanized mice, with **no detectable B cells** in blood, bone marrow or spleen **14 days post-treatment**
- **Benchmark: Partially depleted B cells** in bone marrow; B cells in blood and spleen were eliminated by Day 3 but began recovering by Day 5
- **Cytokine Release: ATG-201 induced significantly lower IL-6 and TNF-α release** compared to Benchmark 4







ATG-201
BMK

B Cells

Blood



Bone Marrow



Spleen



Proinflammatory Cytokine





ATG-106

CDH6 x CD3 TCE for Ovarian and Kidney Cancers

ATG-106: Globally First-in-class CDH6 x CD3 TCE 2.0 for the Treatment of Ovarian and Kidney Cancers

ANTENGENE

CDH6 is a TAA Highly Expressed in Solid Tumors Such as Ovarian Cancer, Renal Cancer, and Endometrial Cancer

TCGA Data Set



- **First-in-class Opportunity:** No CDH6 x CD3 TCE competitors in development yet
- **Compelling Preclinical Profile:** Demonstrated CDH6-dependent T cell activation, potent *in vitro* and *in vivo* anti-tumor efficacy, and good developability, well tolerated in NHP
- **IND Submission Timeline:** Planned for **Q1 2027**

ATG-106 Demonstrates Potent *In Vivo* Anti-tumor Efficacy in Renal Cell Carcinoma Model with Mild and Transient Cytokine Release





ATG-112

ALPPL2 x CD3 TCE for Gynecological Cancer, Non-small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma

ATG-112: ALPPL2 x CD3 TCE 2.0 for the Treatment of Gynecological Cancer, Non-small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma

ANTENGENE

- **First-in-class Opportunity:** No ALPPL2 x CD3 TCE competitors in clinical-stage yet
- **Compelling Preclinical Profile:** Demonstrated ALPPL2-dependent T cell activation, potent *in vitro* and *in vivo* anti-tumor efficacy
- **PCC Nomination:** Planned for **Q1 2026**

ALPP/ALPG is Highly Expressed in Multiple Tumor Types with Restricted Normal Tissue Expression



ATG-112 Demonstrated Promising Pre-clinical Anti-tumor Efficacy



Source: Cancer Res (2020) 80 (20): 4552–4564.; J Pathol Clin Res . 2021 Nov;7(6):577-589. doi: 10.1002/cjp2.237.

Other AnTenGager™ TCEs for Solid Tumors

Other AnTenGager™ TCEs for Solid Tumors

ATG-110: LY6G6D x CD3 TCE 2.0 for MSS Colorectal Cancer











- LY6G6D is a phosphatidylinositol (GPI)–anchored cell surface protein with **expression highly specific to colorectal cancer**
- LY6G6D has much higher expression level in colorectal cancer tissue compared to normal tissue, **predominantly in pMMR/MSS colorectal cancer which has primary resistance to ICI treatment**
- **ATG-110 demonstrated potent efficacy and good stability**
- **IND Submission:** Planned for H1 2027

Undisclosed AnTenGager™ TCE Programs

ATG-115

Undisclosed TAA Bispecific TCE for Liver Cancer

- ✓ Novel tumor associated antigen (TAA) **identified by AI + bioinformatics**
- ✓ **Highly expressed in liver cancer** with low normal tissue expression

2 Undisclosed Trispecific TCEs

- ✓ Targeting **metastatic castration-resistant prostate cancer (mCRPC)** and **small cell lung cancer (SCLC) / neuroendocrine tumors**, respectively
- ✓ **First-in-class Potential**
- ✓ **Enhancing efficacy with reduced toxicity**

ATG-021

GPRC5D x CD3 TCE for Multiple Myeloma

ATG-021: GPRC5D x CD3 TCE 2.0 for the Treatment of Multiple Myeloma

ANTENGENE

- **Best-in-class Opportunity:** Demonstrated better *in vivo* efficacy and induced much lower cytokine release compared with clinical benchmarks
- **Designed for Improved Safety:** GPRC5D-dependent CD3 binding and conditional T cell activation with silent Fc to reduce potential toxicity

GPRC5D is a Validated Target for Multiple Myeloma





ATG-021 Demonstrated Excellent In Vivo Efficacy, Inducing Much Lower Cytokine Release Compared with Benchmark (BMK) TCE







ANTENGENE

ATG-102

LILRB4 x CD3 TCE for Acute Myeloid Leukemia & Chronic Myelomonocytic Leukemia

ATG-102: Biparatopic “2+1+1” LILRB4 x CD3 TCE 2.0 for the Treatment of Acute Myeloid Leukemia (AML) & Chronic Myelomonocytic Leukemia (CMML)

ANTENGENE

- **Biparatopic Design:** Recognizes two non-overlapping epitopes of LILRB4 in a “2+1+1” configuration enabling trivalent LILRB4 binding
- **Compelling Preclinical Profile:** Demonstrated LILRB4-dependent T cell activation, potent *in vitro* and *in vivo* anti-tumor efficacy

LILRB4 is Highly Expressed in Hematological Malignancies













ATG-102 Demonstrates Superior Inhibition of AML Tumor Growth Versus Benchmark in the THP-1 CDX Model





Source: Science. 2009 June 26; 324(5935): 1670-1673; Nature. 2018 Oct;562(7728):605-609.; Cancer Discovery. 2020;10:536-51.; Mol Ther. 2018 Oct 3;26(10):2487-2495.

AnTenGager™ Collaboration Opportunities

ANTENGENE

AnTenGager™ T Cell Engager Platform

- ✓ **"2+1" Bivalent Binding** to DAA to Increase Avidity and Specificity
- ✓ Conditional T cell Binding and Activation via **Steric Hindrance**
- ✓ **Proprietary Anti-CD3 Library** (Affinity: 10^{-6}M to 10^{-9}M) Binding CD3εγ/εσ Complex with Fast On/Fast Off Binding Kinetics
- ✓ Broad Applicability Across **Autoimmune Diseases, Solid Tumors and Hematological Malignancies**

License Existing Programs

Access and advance our validated TCE pipeline assets

Co-Discover/Co-Develop Novel TCEs

Start with an idea, we are open to co-discovery and co-development of innovative TCEs from the ground up

Bring Your Own Binder

With your own binder against a DAA, leverage the platform to generate and optimize novel TCEs



4

Closing Remarks

ANTENGENE

Antengene's Best / First-in-Class Pipeline: Advancing Next-Generation ADCs and Proprietary Novel TCEs for Oncology and Autoimmune Diseases

ANTENGENE

Next Generation ADCs

AnTenGager™ Proprietary TCE Platform

(2nd Generation "2+1" TCE Platform with Steric Hindrance Masking Technology)

Multiple APAC Markets Commercialization

* Approved markets in China also includes Taiwan, Hong Kong, and Macau

Antibody Drug Conjugates (ADCs)

ATG-022 (CLDN18.2) *Phase II*	CLDN18.2+ Gastric Cancer (GC) and Other Solid Tumors	CLDN18.2 ADC with Efficacy Across the Widest Patient Population; BTD in GC
ATG-125 (B7-H3 x PD-L1) *Pre-clinical*	Solid Tumors	IO+ADC in One Drug
CD24 *Pre-clinical*	Solid Tumors	IO+ADC in One Drug

Immuno-Oncology (IO)

ATG-037 (CD73) *Phase Ib/II*	CPI-resistant Melanoma and Non-small Cell Lung Cancer	Oral Bioavailable; Demonstrated Efficacy in CPI-resistant Patients
ATG-101 (PD-L1 x 4-1BB) *Phase I*	Solid Tumors	No Liver Toxicity

Autoimmune Diseases

ATG-201 (CD19 x CD3) *IND submissions expected 1Q26*	B Cell Driven Autoimmune Diseases	Deep B Cell Depletion with Low CRS
ATG-207 (Undisclosed Bifunctional Biologics) *Discovery*	T Cell Driven Autoimmune Diseases	First-in-Class; Induces T_{reg} and T Cell Exhaustion

T Cell Engagers (TCEs)

ATG-201 (CD19 x CD3) *IND submissions expected 1Q26*	B Cell Driven Autoimmune Diseases	Deep B Cell Depletion with Low CRS
ATG-106 (CDH6 x CD3) *Pre-clinical*	Ovarian Cancer and Kidney Cancer	First-in-Class CDH6 TCE
ATG-112 (ALPPL2 x CD3) *Pre-clinical*	Gynecological Tumors and Lung Cancer	First-in-Class ALPPL2 TCE
ATG-110 (LY6G6D x CD3) *Pre-clinical*	Microsatellite Stable (MSS) Colorectal Cancer	For IO-resistant Colorectal Cancer
ATG-021 (GPRC5D x CD3) *Pre-clinical*	Multiple Myeloma	
ATG-102 (LILRB4 x CD3) *Pre-clinical*	Acute Myeloid Leukemia and Chronic Myelomonocytic Leukemia	Biparatopic
ATG-107 (FLT3 x CD3) *Pre-clinical*	Acute Myeloid Leukemia	
ATG-115 (Undisclosed Bispecific TCE) *Pre-clinical*	Liver Cancer	Novel TAA Discovered by AI
Undisclosed Trispecific TCE *Discovery*	Metastatic Castration-resistant Prostate Cancer	First-in-Class
Undisclosed Trispecific TCE *Discovery*	Small Cell Lung Cancer and Neuroendocrine Tumors	First-in-Class

Antengene Well Positioned for Long-Term Growth with Expanding Revenue, Pivotal-Stage Pipeline, and Robust R&D Innovation

ANTENGENE

Clinical Stage Drugs Entering Pivotal Trials

Multiple Market Commercialization + Partnering Revenues

Robust R&D Engine Driving Novel Drug Innovation

Q&A Session

德琪医药
ANTENGENE

Thank You!

BD Contact: ariel.guo@antengene.com | Investor Contact: IR@antengene.com